WallStreetZenWallStreetZen

NASDAQ: HALO
Halozyme Therapeutics Inc Stock Ownership - Who owns Halozyme Therapeutics?

OverviewForecastEarningsRevenueDividendOwnership

Insider buying vs selling

Have Halozyme Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Helen TorleyPRESIDENT AND CEO2025-12-01500$70.36
$35.18kSell
Bernadette ConnaughtonDirector2025-12-01829$71.60
$59.36kSell
Helen TorleyPRESIDENT AND CEO2025-12-01261$71.60
$18.69kSell
Helen TorleyPRESIDENT AND CEO2025-12-0110,406$68.51
$712.94kSell
Helen TorleyPRESIDENT AND CEO2025-12-015,402$69.44
$375.12kSell
Helen TorleyPRESIDENT AND CEO2025-12-0116,569$8.11
$134.37kBuy
Helen TorleyPRESIDENT AND CEO2025-11-12498$71.67
$35.69kSell
Helen TorleyPRESIDENT AND CEO2025-11-1212,718$70.22
$893.03kSell
Helen TorleyPRESIDENT AND CEO2025-11-1220,000$8.11
$162.20kBuy
Helen TorleyPRESIDENT AND CEO2025-11-126,784$71.09
$482.27kSell

1 of 12

HALO insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when HALO insiders and whales buy or sell their stock.

HALO Shareholders

What type of owners hold Halozyme Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Randal J. Kirk22.65%26,633,924$1.80BInsider
Blackrock Inc10.94%12,860,199$870.64MInstitution
Vanguard Group Inc9.89%11,629,786$787.34MInstitution
State Street Corp4.27%5,019,207$339.80MInstitution
Gregory Ian Frost3.10%3,641,380$246.52MInsider
Arrowstreet Capital Limited Partnership2.80%3,290,665$222.78MInstitution
Invesco Ltd2.76%3,245,770$219.74MInstitution
Ubs Group Ag2.50%2,945,751$199.43MInstitution
Snyder Capital Management L P2.32%2,733,844$185.08MInstitution
D E Shaw Co Inc2.25%2,650,375$179.43MInstitution

1 of 3

HALO vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
HALO77.68%22.32%Net SellingNet Selling
CYTK90.23%9.77%Net SellingNet Selling
PRAX63.75%36.25%Net SellingNet Selling
NUVL75.78%24.22%Net SellingNet Selling
KRYS79.21%20.79%Net SellingNet Selling
View Top Biotech Stocks

Halozyme Therapeutics Stock Ownership FAQ

Who owns Halozyme Therapeutics?

Halozyme Therapeutics (NASDAQ: HALO) is owned by 102.40% institutional shareholders, 29.42% Halozyme Therapeutics insiders, and 0.00% retail investors. Randal J. Kirk is the largest individual Halozyme Therapeutics shareholder, owning 26.63M shares representing 22.65% of the company. Randal J. Kirk's Halozyme Therapeutics shares are currently valued at $1.79B.

If you're new to stock investing, here's how to buy Halozyme Therapeutics stock.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.